SM
PHIO icon

Sabby Management’s Phio Pharmaceuticals PHIO Stock Holding History

Sabby Management’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13
Closed -$281K – 206
2021
Q3 		$281K Sell
13
-2
-13% -$418 0.04% 134
2021
Q2 		$366K Hold
15
– – 0.05% 118
2021
Q1 		$427K Buy
+15
New +$4.99K 0.08% 116

Other funds holding PHIO

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Sabby Management's PHIO Position: Q4 2024 in Review

Sabby Management sold out of Phio Pharmaceuticals (PHIO) in Q4 2024, closing a stake of 25,131 shares — an estimated $86.7K sold.

Sabby Management first reported a position in PHIO in Q4 2016 and held it in 11 quarters. The position peaked at $520K in Q4 2018. 11 funds tracked by Wall St. Rank hold PHIO as of Q4 2024.

  • Sabby Management reported no remaining Phio Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Sabby Management sold 25,131 Phio Pharmaceuticals shares in Q4 2024, an estimated $86.7K.
  • Sabby Management first reported a position in Phio Pharmaceuticals in Q4 2016 and held it in 11 quarters.
  • Sabby Management's Phio Pharmaceuticals position peaked at $520K in Q4 2018.
  • 11 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q4 2024.

Based on Sabby Management's 13F filing for Q4 2024, filed 14 Feb 2025.